Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma

The outcome in esophageal adenocarcinoma (EAC) is still poor with only 20% of patients in Western populations surviving for more than 5 years. Almost nothing is known about the precise composition of immune cells and their gene expression profiles in primary resected EACs and also nothing compared t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Immunol Immunother
Main Authors: Wagener-Ryczek, Svenja, Schoemmel, Max, Kraemer, Max, Bruns, Christiane, Schroeder, Wolfgang, Zander, Thomas, Gebauer, Florian, Alakus, Hakan, Merkelbach-Bruse, Sabine, Buettner, Reinhard, Loeser, Heike, Thelen, Martin, Schlößer, Hans A., Quaas, Alexander
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113210/
https://ncbi.nlm.nih.gov/pubmed/31960110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02475-w
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares